Clinical Trial Update: A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating single-agent Inavolisib, Inavolisib plus Atezolizumab, and Inavolisib plus Pembrolizumab in PIK3CA-mutated cancers; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Inavolisib (Inavolisib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: PIK3CA-Mutated Cancers | Phase 1 | Status: RECRUITING